Amgen shares jump after Sjögren’s trial win; Citi flags open questions
Amgen (AMGN) said its experimental drug dazodalibep reduced disease intensity in late-stage moderate-to-severe systemic Sjögren’s disease, lifting shares up to ~5% on Tuesday. Citi flagged “open questions.”
Shares of Amgen (AMGN) rose as much as 5% on Tuesday after the company said its experimental autoimmune drug dazodalibep reduced disease intensity in patients with moderate-to-severe systemic Sjögren’s disease in a late-stage study. At the time of writing, AMGN was trading 4% higher as investors…